Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Claim Objections
The word “is” should be inserted after the word “heteroatom” in line 1 of claim 4.
Claim Rejections - 35 USC § 112
The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
Claims 1-14 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention.
As an initial matter, Applicant defines the invention as a curable composition but it is not clear what is the curing mechanism if not via the hydrolysis/condensation of residual alkoxy group present upon formation of the siloxane resin. However, there is nothing in claim 1 stipulating the mandated presence of groups X and, thus, the curability of the resin is in question at least in these instances. It is speculated that perhaps curing involving the boron groups is possible and, until Applicant clarifies the record, it will be presumed for the purpose of evaluating the instant invention against the prior art that this supposition is correct. (This forms the basis for the rejection that follows insofar as it anticipates a permutation of the claimed resin for which p=0 in each unit.)
Concerning claim 12, while it is the Examiner’s belief that Applicant intends to claim embodiments of a siloxane “resin” having exactly two (dimer) or three (trimer) silicon atoms, this presumption is thrown into doubt because the dimer and trimer are said to be obtained by the partial condensation of two or three siloxane molecules, as opposed to silane molecules. The Examiner contends that no siloxane compound that may be conceived of could undergo condensation and yield a siloxane dimer or trimer.
Claim Rejections - 35 USC § 102
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.
Claims 1-11, 13, and 14 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Branlard et al., WO 00/20425.
Applicant is referred to Examples 4 and 5 where tetracyclosiloxanes bearing a boron-containing group is bound to each ring silicon atom. These compounds conform with formula (I) of claim 1 where n=1, m=1, p=0, q=2, Z is a C3 alkylene, and R1 is a methyl group.
Claims 4, 6, and 8-9 are rejected because they are further limiting of an embodiment of the instant invention that did not constitute the Examiner’s grounds for rejection. That is to say, in claim 4, for instance, the identity of an optional heteroatom is defined but the rejection is predicated on those permutations of R1 and Z where a heteroatom is absent. A similar rationale explains why claims 6 and 8 are deemed unpatentable.
As for claim 14, it is stated at the bottom of page 5 of the translated document that the prior art boron-functionalized siloxane compounds have utility as coating materials.
The article entitled “Probing the Source of Enhanced Activity in Multiborylated Silsesquioxane Catalysts for C-O Bond Reduction” authored by Starr et al. and published in Organometallics (2022) 41, 3152-3160 teaches as catalysts the hydroboration product of octavinylsilsesquioxane with HB(C6F5)2 in a slightly substoichiometric amount (7.5 equivalents) of the latter relative to the number of moles of vinyl groups furnished by the aforementioned polyvinylated silsesquioxane. See the first paragraph under the heading RESULTS AND DISCUSSION and the generalized representation at the top of the cover page of a boron group being attached via a divalent ethylene bridge at each of the 8 vertices of the compound. This compound adheres to formula (I) of claim 1 wherein=1, m=0, p=0, and q=3, Z is -CH2CH2- and Y is -B(C6F5)2. The efficacy of this compound as a promoter of a chemical conversion in a small molecule is taught but there is no disclosure of it having utility as a curing catalyst in a composition that undergoes cure. (There is nothing requiring claimed component (A) to play a particular role and, indeed, it could be a catalyst, or co-catalyst, for the composition in which case it may be of overlapping scope with claimed component (B)… this being the Examiner’s broadest reasonable interpretation of the scope of the claims.)
Any inquiry concerning this communication or earlier communications from the examiner should be directed to MARC S ZIMMER whose telephone number is (571)272-1096. The examiner can normally be reached M-F 8:30-5:00.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Heidi Kelley can be reached at 571-270-1831. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
October 16, 2026
/MARC S ZIMMER/Primary Patent Examiner, Art Unit 1765